- Jean-Pierre Garnier, chief executive of GlaxoSmithKline, said it had been a difficult year.
- The company absorbed over Â£1.5bn of lost sales to generics but still managed to grow the business.
- 2005 will also be an important year in terms of research and development pipeline progress.
- The firm discontinued development of an experimental treatment for obesity after disappointing clinical trial results.
